Part three of the trial will involve patients at higher risk of cardiovascular disease due to obesity and elevated CRP levels.

--Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader- based medicines, today reported a clinical update, business highlights, and ...

Monte Rosa discovered that GSPT1 is a synthetic lethal target for cancers expressing any member of the Myc family, namely c-Myc, l-Myc or n-Myc. Synthetic lethality is the interaction between two ...

Monte Rosa was launched from Ridgeline, Versant’s Discovery Engine based in the Basel Technology Park. The company is now headquartered in Boston, MA, with research operations in both Boston and ...

Owen Wallace, Ph.D., Chief Scientific Officer of Monte Rosa, added, “Advancing our first development candidate into IND-enabling activities is one of the most important milestones for our ...

Monte Rosa Therapeutics (GLUE) reported an update from its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors. MRT-2359 is an investigational ...

Monte Rosa's CEO, Markus Warmuth, expressed enthusiasm about Dr. Hughes joining the board, highlighting his expertise in R&D and drug development, which will be invaluable as the company expands ...

Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to ...

Monte Rosa will also be eligible for future payments of up to $2.1 billion as well as royalties on net sales outside the U.S.

Boston-based Monte Rosa said Thursday that it had raised a Series B round of $96 million. Aisling Capital led the round, while founding investor Versant Ventures participated, along with New ...

Monte Rosa Therapeutics Trading Down 5.6 % Monte Rosa Therapeutics stock opened at $6.03 on Tuesday. The firm has a 50 day moving average of $6.20 and a 200 day moving average of $6.77.